Blog

Funding backs a human-first approach to drug safety and efficacy, reducing reliance on animal testing and accelerating therapies for patients.

NEW HAVEN, CT / ACCESS Newswire / December 5, 2025 / Revalia Bio (Revalia), developer of the Human Data Trial platform, today announced that they are serving as the technical lead for an up to $26.7M contract that they were awarded under the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. The project, titled An Integrated Human Data Approach to Unlock the Future of In Silico Learning Models, supports Revalia’s mission to redefine how drug safety and efficacy are predicted before clinical trials.

Revalia will lead the effort to build advanced AI-driven models trained on Human Data Trials, living systems derived from donated human organs, organ-on-chip platforms, and multimodal datasets. The goal is to reduce reliance on animal models and better predict how drugs behave in the human body, cutting costly late-stage failures and accelerating safer therapies.

“This award is a turning point for Revalia and for the broader field of human-based trials,” said Greg Tietjen, PhD, CEO and Co-Founder of Revalia. “It’s a validation for us that confirms that the era for human data is here. Donated human organs are the Rosetta Stone of human-centered development, and our Human Data Trials platform transforms that gift into actionable insight for safer, more effective drugs. Most importantly, this program allows us to further deliver on our mission to honor the legacy of every donor by turning the loss of one life into knowledge that shapes the future of medicine.”

A Human-First Alternative to Animal Models

The ARPA-H CATALYST program is designed to accelerate safer, faster drug development by enabling more accurate predictions of safety and efficacy in investigational new drugs (INDs). CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D. Revalia’s integrated approach aligns with recent NIH and FDA initiatives to reduce reliance on animal testing by providing rigorous, clinically grounded human datasets to support regulatory innovation.

“Drugs should be tested in the same biology, from the same patients, they are meant to treat,” said Janet Nikolovski, PhD, Chief Data and Innovation Officer at Revalia. “We are generating a unique, integrated human dataset encompassing everything from high level patient data to organ specific physiology and comprehensive molecular level analyses. These data will train models that we believe will better simulate clinical outcomes and reduce the risk of drug failure in clinical trials. This has the potential to change the paradigm for drug development, bringing better and faster therapies to patients who need them.”

Collaborative Ecosystem: The Human Data Stack

Revalia’s Human Data Trials platform forms the foundation of the company’s broader Human Data Stack, a framework that integrates donor organs, organoids, and organ-on-chip systems into a unified translational system. Revalia will collaborate with a national consortium that brings together:

• A leading engineering research institute developing high-dimensional datasets through advanced platforms.

• A regional nonprofit organization focused on expanding access to organ donation for scientific study.

• An academic research lab specializing in artificial intelligence and machine learning to unlock predictive insights.

• A top 10 pharma company looking to integrate New Approach Methodologies (NAMs) into their standard workflows to accelerate the pace of pre-clinical development

“This project unites clinicians, biologists, engineers, and AI/ML experts to build advanced in silico models of human physiology that predict drug metabolism, pharmacokinetics, and toxicity,” said Nabil Boutagy, PhD, Director of Human Data Trial Operations at Revalia. “By integrating diverse expertise and generating multi-omic data at scale, we aim to cut drug development costs and timelines while guiding optimal dosing for patients.”

ABOUT REVALIA BIO:

Revalia Bio is transforming how new medicines are developed by offering on-demand access to real, functional human data. Built on decades of research in human organ perfusion, Revalia’s platform enables rigorous testing in donated human organs maintained under clinical conditions. This makes it possible to run Human Data Trials – studies that generate trial-quality data on safety, efficacy, and mechanism at any stage of development, before a molecule ever reaches a patient. For more information, visit www.revaliabio.com.

MEDIA CONTACT:

Nina Pfister, MAG PR at E: nina@mooringadvisorygroup.com; P: 781-929-5620

SOURCE: Revalia Bio

View the original press release on ACCESS Newswire

ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip Small Stocks, Big Money^™ show, a sponsored program on Bloomberg TV this Saturday, December 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• CLDI: https://www.redchip.com/assets/access/cldi_access

• NVA: https://www.redchip.com/assets/access/nva_access

In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi, will appear on the RedChip Small Stocks Big Money^™ show on Bloomberg TV to discuss Calidi’s pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic and difficult-to-treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human cell-derived envelope, allowing the virus to evade immune detection and find and specifically replicate in tumor cells at metastatic sites. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The Company is advancing toward IND filing by the end of 2026. Calidi’s capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight the Company’s strong potential to deliver value to shareholders.

Christopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks Big Money^™ show on Bloomberg TV to outline the Company’s strategy to advance its Estelle Project in Alaska-one of North America’s largest undeveloped gold systems and a rapidly emerging U.S. critical minerals asset. Spanning 514 km² in the world-renowned Tintina Gold Belt, Estelle hosts a 35 km mineralized corridor with more than 20 gold and antimony prospects, including two defined multi-million-ounce gold resources and several drill-ready antimony targets with visible stibnite at surface. Gerteisen will highlight Nova’s dual-pronged development strategy: accelerating its path to becoming a tier-one gold producer while simultaneously establishing the first fully domestic, integrated U.S. antimony supply chain in decades-supported by a transformational US$43.4 million Defense Production Act Title III award from the U.S. Department of War. With military-grade antimony production targeted for 2026/27, active discussions underway with federal agencies and industrial partners, and a feasibility study progressing to expand the current 5.2-million-ounce gold resource, Nova is positioning itself as a strategically vital North American supplier at the intersection of critical minerals security and large-scale gold development.

CLDI and NVA are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

About Nova Minerals Limited

Nova Minerals Limited is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project, comprised of 514 km² of State of Alaska mining claims, which contains multiple mining complexes across a 35 km long mineralized corridor of over 20 advanced Gold and Antimony prospects, including two already defined multi-million ounce resources, and several drill ready Antimony prospects with massive outcropping stibnite vein systems observed at surface. The 85% owned project is located 150 km northwest of Anchorage, Alaska, USA, in the prolific Tintina Gold Belt, a province which hosts a >220 million ounce (Moz) documented gold endowment and some of the world’s largest gold mines and discoveries, including Kinross Gold Corporation’s Fort Knox Gold Mine. The belt also hosts significant Antimony deposits and was a historical North American Antimony producer.

Further discussion and analysis of the Estelle Project is available through the interactive Vrify 3D animations, presentations, and videos, all available on the Company’s website. www.novaminerals.com.au

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money^™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money^™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat^™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit: https://www.redchip.com/corporate/investor_relations

“Discovering Tomorrow’s Blue Chips Today”^™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
info@redchip.com

–END–

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

National Center for Civil and Human Rights Unveils Broken Promises Gallery “Guided” by Ida B. Wells

ATLANTA, GEORGIA / ACCESS Newswire / December 5, 2025 / The National Center for Civil and Human Rights’ new gallery, “Broken Promises,” is a permanent exhibit on Reconstruction-the period after the Civil War and Emancipation when America first attempted to build a multi-racial democracy. The Center invites people to experience the new gallery which opens to the public today, December 5, 2025, as part of the Center’s $58 million expansion.

The gallery presents Black progress during the Reconstruction Era, when nearly four million newly freed Black Americans claimed their rights as citizens, voted, won elected office, created schools, and reshaped economic and civic life across the South. It also presents the violent backlash that met and then suppressed those gains – through racial terror, political disenfranchisement, and Jim Crow legal segregation.

“Reconstruction reminds us that the expansion of rights in America has never moved in a straight line. Every reform toward wider freedom has been accompanied by efforts to limit those rights,” said Jill Savitt, the CEO of the Center. “Recognizing that pattern helps us understand the forces that have long shaped America, up until today.”

Curated by the Center’s Chief Program Officer, Kama Pierce, the gallery has anti-lynching crusader Ida B. Wells as its “docent,” and focuses on three cities – Wilmington, N.C., Atlanta, Ga., and Tulsa, Okla. In each city, Black achievement provoked white backlash that resulted in massacres and racial terror.

The immersive gallery contains artifacts from the Without Sanctuary Collection, including a fragment of a noose and photographs of lynchings that were turned into postcards for entertainment. The artifacts deepen visitors’ understanding of how racial terror was wielded as a strategy.

The gallery’s memorial space features a historical marker honoring Mary Turner, who was lynched in 1918. Turner’s family erected the public marker to honor her – but it was consistently defaced. The family donated the marker — marred by 11 bullet holes — to the Center. Artist Lonnie Holley has interpreted the marker in the gallery’s memorial space.

“The Mary Turner marker is a powerful artifact that bears witness twice – first to the original terror, and again to the present resistance to let the truth be told,” said Pierce.

The Center decided to add a gallery on Reconstruction because the era has not always been fully or accurately represented in American classrooms. The Center also wanted to provide more context for its signature gallery on the Civil Rights Movement.

“After Reconstruction, the United States entered a decades-long period of Jim Crow segregation and unequal protection for Black Americans,” said Pierce. “The Civil Rights Movement emerged not as a new struggle, but as a renewed demand to enforce the promises first made during Reconstruction.”

The Center received a $2 million grant from the Mellon Foundation for the exhibition.

About the National Center for Civil and Human Rights
The National Center for Civil and Human Rights is a museum and cultural organization that inspires the changemaker in each of us. Opened in 2014, the Center connects US civil rights history to global human rights movements today. Our experiences highlight people who have worked to protect rights and who model how individuals create positive change. For more information, visit civilandhumanrights.org. Follow us on Facebook, Twitter, Instagram @civilandhumanrights and LinkedIn at linkedin.com/company/ncchr.

###

Contact Information
Tenisha Griggs
Head of Marketing
tgriggs@civilandhumanrights.org
404-973-7710

SOURCE: National Center for Civil and Human Rights

View the original press release on ACCESS Newswire

New Institutional Investment Vehicle Expected to Drive Awareness, Liquidity, and Value to Bonk, Inc.’s Treasury

SCOTTSDALE, AZ / ACCESS Newswire / December 5, 2025 / Bonk, Inc. (Nasdaq:BNKK) today welcomed a significant development within the broader BONK ecosystem that directly supports the Company’s strategic objective of building shareholder value through digital asset treasury accumulation.

The Company highlighted the recent launch of the BONK Exchange Traded Product (ETP) by Bitcoin Capital AG on the SIX Swiss Exchange.

Mitchell Rudy (a.k.a. Nom), a BONK core contributor and Board Director, commented on the significance of this development: “The momentum we are seeing is undeniable. The ecosystem is expanding rapidly, and institutional financial rails are being built in the EU to broaden access for investors. Bonk, Inc. is positioned perfectly in the center of this growth. We own the treasury, and we are aggressively expanding our portfolio of revenue-generating infrastructure. As the ecosystem grows, Bonk, Inc. grows.”

Market Validation: The “ETP Effect” on Europe’s Third-Largest Exchange The launch of the BONK ETP on the SIX Swiss Exchange-Switzerland’s largest and Europe’s third-largest stock exchange-represents a critical maturation point. This listing allows investors to buy and sell the BONK digital asset just like traditional stocks, without needing specialized expertise or complex digital wallets.

Bitcoin Capital AG, a Swiss-based issuer known for bridging the gap between traditional finance and digital assets, issued the product. The move is widely seen as a major step in the asset’s progression from its community-driven origins to a respected financial asset.

Marcel Niederberger, CEO of Bitcoin Capital, stated in the launch announcement: “With the Bonk ETP now listed on SIX Swiss Exchange, investing in Bonk has never been easier. Investors don’t need [digital asset] expertise; they can trade Bonk just like any other stock. We’re making community-driven digital assets accessible to everyone, while meeting high security and regulatory standards.”

The “Flywheel Effect”: Fueling the Corporate Growth Engine Bonk, Inc. views this third-party development as a direct accelerator for its dual-engine business model. By bridging the gap between traditional finance and the BONK ecosystem, the regulated ETP supports the Company’s growth in two distinct ways:

• Treasury Appreciation: The introduction of a regulated investment vehicle historically lowers barriers for institutional capital. Increased demand and global awareness serve to support the fundamental value of the BONK digital assets held on Bonk, Inc.’s balance sheet.

• Ecosystem Velocity: As the asset gains legitimacy and visibility on global exchanges, it attracts new users and liquidity to the Solana network. This increased activity ultimately drives transaction volume to ecosystem infrastructure like Bonk.fun, where Bonk, Inc. holds a majority revenue interest.

“We are witnessing the rapid maturation of the asset class we have anchored our company to,” added Jarrett Boon, CEO of Bonk, Inc. “The launch of a regulated ETP on a major European market like the SIX Swiss Exchange is a watershed moment. For our shareholders, this is strictly good news. This key institutional on-ramp drives the awareness and activity that ultimately fuels the value of our treasury.”

About Bonk, Inc. Bonk, Inc. (Nasdaq:BNKK) is a company evolving to bridge the gap between traditional public markets and the digital asset ecosystem. Through its subsidiary BONK Holdings LLC, the Company executes a strategy focused on acquiring revenue-generating assets within the DeFi space. The Company also operates a growing beverage division holding the patented Sure Shot and Yerbaé brands.

Investor Relations Contact: Phone: 888.257.8061 Email: investors@bonkdat.com

Forward-Looking Statements: This press release contains forward-looking statements. Such statements are subject to risks and uncertainties, and actual results could differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the performance of BONK digital assets, the adoption of new ecosystem products, market volatility, and other risks detailed in Bonk, Inc.’s filings with the Securities and Exchange Commission.

SOURCE: Bonk, Inc.

View the original press release on ACCESS Newswire

MONROE TOWNSHIP, N.J / ACCESS Newswire / December 5, 2025 / Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American:OPTT) today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Bob Powers, CFO of OPT will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about OPT at Home – Ocean Power Technologies.

Event Details:

• 3rd Annual DealFlow Discovery Conference

• The Borgata Hotel, Casino & Spa

• Atlantic City, NJ

• January 28-29, 2026

Investors interested in scheduling a meeting with the OPT management team should request an investor pass to attend the conference (no cost to attend).

About OPT

OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI-capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V® unmanned surface vehicles (USV’s) and marine robotics services. The Company’s headquarters is located in Monroe Township, New Jersey and has an additional office in Richmond, California. To learn more, visit www.OceanPowerTechnologies.com.

Media Contact:

Bob Powers
CFO
OPT
(609) 730-0400
rpowers@oceanpowertech.com

SOURCE: Ocean Power Technologies, Inc.

View the original press release on ACCESS Newswire

SASKATOON, SASKATCHEWAN / ACCESS Newswire / December 5, 2025 / MAGNUS Construction Services has been recognised with the 2025 Consumer Choice Award in the Insulation Contractor category for Saskatoon. This recognition underscores the company’s leading role in spray foam, thermal, and moisture protection across Saskatchewan.

Proudly family-owned and operated, MAGNUS Construction Services brings over 16 years of experience and a portfolio of more than 7,000 completed residential and commercial projects. Built on a foundation of quality and trust, the team relies on high-performance Canadian products engineered to withstand the region’s demanding prairie climate.

“At MAGNUS, we believe in protecting more than buildings,” says the Magnus Construction Services team. “We safeguard comfort, efficiency, and indoor health-all year long. This award reflects the confidence our clients have in us to get it right every time.”

Tailored Insulation Solutions for Every Project

MAGNUS delivers comprehensive insulation and thermal protection services, tailored to the unique needs of each project:

Residential: Whole-home envelope systems including attic, wall, basement, garage, under slab and foundation spray foam; fiberglass and mineral wool options; air seal,insulation extraction and renovations, drywall, texture and waterproofing services.

Commercial: Thermal barriers, fire-proofing, fire-stopping, high-performance foundation waterproofing systems, flat roof restoration, vapor barriers, drywall, asbestos abatement, and more.

Specialty Projects: Premium Spray Foam and Specialty Coatings for Quonsets, metal buildings, containers, restoration services, and transport applications like custom vans.

Additionally, their spray foam-featuring Insulthane Extreme, best Canadian closed-cell Spray Polyurethane Foam-offers lowest permeability, best dimensional stability, superior R-Value, air and vapour sealing, resistance to mold, pests, and highest overall Thermal Efficiency.

Recognition Rooted in Performance and Professionalism

Winning the Consumer Choice Award reflects MAGNUS’s commitment to excellence and consistent customer satisfaction. Built on dependable workmanship and a safety-first mindset-evident through rigorous employee training and a focus on long-term performance-the award reaffirms their reputation in the community.

Looking Forward with Industry-Leading Standards

As they celebrate the 2025 Consumer Choice Award, MAGNUS’s Construction Services remains dedicated to innovation and quality. By staying ahead with advanced insulation methods and investing in people and training, the company is poised to continue delivering energy-efficient, healthy, and durable environments for Saskatchewan homes and businesses.

To learn more or request a consultation, visit www.magnusconstruction.ca or CLICK HERE.

About MAGNUS’s Construction Services
MAGNUS’s Construction Services is a Saskatoon-based, family-owned provider of moisture and thermal protection solutions. Leveraging over 16 years of experience and more than 7,000 projects, the team delivers tailored, high-performance spray foam, fiberglass, and specialty insulation services across residential, commercial, and unique applications-designed specifically for Saskatchewan’s climate. Learn more at www.magnusconstruction.ca.

About Consumer Choice Award
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire